微芯生物(688321.SH):清華大學持有的清華控股100%股權將無償劃轉給四川能投
格隆匯12月12日丨微芯生物(688321.SH)發佈公吿,清華大學擬通過無償劃轉方式將清華大學持有的清華控股有限公司(以下簡稱“清華控股”)100%的股權劃轉給四川省能源投資集團有限責任公司(以下簡稱“四川能投”)。清華大學本次劃轉需獲得中國教育部批覆,四川能投本次受讓需獲得四川省國資委相關審批批覆。
若本次無償劃轉實施完成,四川能投將通過博奧生物集團有限公司間接持有公司4291.96萬股,佔公司總股本的10.45%。本次無償劃轉不會導致公司的控股股東、實際控制人發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.